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with neurological symptoms (partial crises in right face). MNRI evidences four lesions in brain and a lot of small intraduralis and
extramedullaris nodules. The big one was removed. The others lesions were treated though craniospinal irradiation (30Gy, 2Gy
per fraction except previous irradiated areas) and radiosurgery in brain lesions.
Conclusions. Myxopapillary ependymoma is a slowly growing, grade I tumour, they have a tendency to affect younger individuals
(mean age 36.4 years) and the vast majority are restricted to the conus medullaris and ﬁlum terminale. The recurrences are
usually conﬁned to the same site as the primary. Myxopapillary ependymomas have been rarely documented to metastasize,
both intra- and extracranially, but these are cases with a long clinical history with local recurrences. Finally, the facts that we
explain in this case show that we have to make a higher follow-up to avoid late recurrences despite some papers recommend
approximately 10 years.
http://dx.doi.org/10.1016/j.rpor.2013.03.121
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Introduction. Bevacizumab is a monoclonal antibody which inhibits VEGF, normalizes vascular permeability and improve edema.
Currently is indicated for the treatment of many solid tumors. In recent years it has been used for the treatment of brain
radionecrosis. The high-grade gliomas express high levels of VEGF and after use of bevacizumab have been observed rapid effect
on the improvement of neurological functions, allowing lower doses of corticosteroids.
Patients and methods. We used bevacizumab in a patient under compassionate use in our center for the treatment of brain
radionecrosis.
Results. 53-year old woman with no relevant medical history was diagnosed of grade II astrocytoma three years ago. The
patient underwent partial resection of the lesion, subsequently receiving radiotherapy dose 50.8Gy. After such treatment
continues follow up. In November 2010 she entered the area of internal medicine secondary to worsening neurological func-
tions. Radiological study was performed showing an extensive radionecrosis after radiotherapy with associated edema. Despite
the use of high-dose corticosteroids she was admitted again two months later. We offer treatment for radionecrosis to the
patient with bevacizumab under compassionate use procedure. The response of the patient after the ﬁrst administration
is excellent with improvement of neurological functions and without use of corticosteroids. She had four sessions of the
treatment, ending in April 2011. Later she carried on periodic reviews and in April 2012, presents a new radiological wors-
ening. We decide to begin a new treatment with bevacizumab. Again the patient showed clinical response with improvement
of neurological functions and currently continues periodic revisions without tumor progression and with a good quality of
life.
Conclusions. Bevacizumab can be considered as alternative therapy for the treatment of cerebral radionecrosis as it improves the
symptoms of patients and allows reduced use of corticosteroids.
http://dx.doi.org/10.1016/j.rpor.2013.03.122
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Introduction. Standard treatment in high grade astrocytomas (HGA) consists of maximal surgical resection, followed by
radiotherapy plus concomitant and adjuvant temozolomide. When relapse or progression occurs, there is no standard
treatment.
Objectives. To analyze the efﬁcacy (overall survival, OS and progression-free survival, PFS) and toxicity of treatment with beva-
cizumab plus irinotecan in patients with HGA in progression after radiotherapy and temozolomide.
Material and methods. Between January 10 and December 12, 15 patients, median age 50±6.4 (43–64), were analyzed retrospec-
tively. 73.3%men and 26.7%women. Complete resection: 8 (53.3%), partial resection: 5 (33.3%) and biopsy: 2 (13.3%). 7 had received
Gliadel® wafer placed in the resection cavity. Histological diagnosis: glioblastoma multiforme (14 patients) and 1 anaplastic astro-
cytoma. Median KPS 90. All patients had received prior radiotherapy with concurrent temozolomide (Stupp regimen). Median of
6±6 cycles (1–26) of adjuvant temozolomide. 7 patients (46.7%) were treated with the extended-schedule dose-dense temozolo-
mide, median of 4±2 cycles (1–7). Bevacizumab was administered with irinotecan every 2 weeks. Patients received treatment
until evidence of progression or unacceptable toxicity. Response was determined by MRI or clinical. Median of 13±12 cycles
(2–50). Mean and standard deviation for quantitative variables and absolute frequency and percentage for qualitative variables
were obtained. The Kaplan–Meier method was used to estimate patient survival.
Results. With a median follow-up of 7 months, 33.3% of patients had progressed and 40% had died. Median OS, 13.6 months. 6-
month OS, 84.6%. Median PFS, 7.2 months. PFS-6, 77%. Median time to progression was 6.6 months. Overall response: 6 patients
(40%), (complete in 2). Stabilization was observed in 3 patients, 3 progression and 3 clinical response. Toxicity: hypertension (2
patients), ﬁstula rectal bleeding (1 patient), and abdominal perforation (1 patient).
S188 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S186–S197
Conclusions. Bevacizumab plus irinotecan in recurrent HGA improves responses, PFS and OS compared with historical data with
low toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.123
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Introduction. Clival chordomas are a rare, locally destructive and slow growing bone tumors that arise from vestiges of the noto-
chord. In adults, about 30% of chordomas occur at the base of the skull. Clival chordomas have a high rate of recurrence and have
rarely been reported to metastasize, this feature and the difﬁculty to achieve tumoral complete resection makes local progression
the most common cause of death. Case description. A 54-year old Caucasian man presented a progressive visual loss of the left
eye during one year. MRI reported a sellar and suprasellar mass of 23mm×24mm×27mm in intimate contact with the optic
chiasm and the third ventricle ﬂoor that deformes the anterior midbrain. Intraoperative exploration and pathological ﬁndings
revealed a clival chordoma. The patient underwent neurosurgery for the ﬁrst time on April 2010. On April 2011 he underwent
surgery again with partial resection because we found a suprasellar relapse of about 29mm×32mm×38mm and radiotherapy
with proton beam therapy was performed as adyuvant treatment on august 2011 in Switzerland. On February 2012 he presented
some behavioral and cognitive disorders and the MRI showed a bilateral hippocampal signal alterations that were ﬁnally diag-
nosed as radionecrosis, a side effect of the proton therapy. The symptoms were resolved with high doses of corticosteroids and
neurological and neuropsychological assessment was made too.
Conclusions. Proton beam therapy is an effective treatment for the local control of clival chordomas, especially for those patients
with small tumors. Despite successful control of these tumors, side effects such radiation necrosis are still a concern.
http://dx.doi.org/10.1016/j.rpor.2013.03.124
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Objectives. This retrospective analysis was performed to determinate the efﬁcacy, safety and feasibility of concurrent
radiochemotherapy (CRCT) followed by adjuvant chemotherapy with temozolomide (TMZ) in the treatment of patients with
malignant gliomas.
Methods. From July 2002 to August 2012, 96 patients with pathologically conﬁrmed malignant glioma were included in this
retrospective analysis. Median age was 62 years (range 27–80 years). Gender: male 61.5%, female 38.5%. The main tumor locations
were frontal or temporal lobe in 59.4% of cases. Preoperative ECOG: 0–1 for 88.5% of the patients. All but 3 patients (96.9%)
underwent surgery (complete resection in 57.3%) and 71.9% of the patients received treatmentwith corticosteroids. CRCT:median
dose of 60Gy (range 30–60Gy) in daily fractions of 2Gy, 5 days per week, for 6 week combined with TMZ (75mg/m2) per day.
Adjuvant chemotherapy: TMZ (150–200mg/m2) up to a median number of 6 (range 0–20) courses.
Results. With a median of follow-up of 43.5 months (range 8–128 months), median survival time was of 10.5 months with actuarial
1 and 2 years overall survival rates of 47.3% and 16.7% respectively. CCRT resulted in grade 3/4 hematologic toxicity in 2.1% of
patients. No cases of grade 5 toxicity were observed. Univariate analysis revelled that the signiﬁcant prognostic factors for overall
survival were: ECOG performance status 0–1 (p<0.00001), age at diagnoses below 60 years (p<0.033), complete tumor resection
(p<0.02), total dose of 60Gy (p<0.0001), concomitant TMZ (p<0.003), adjuvant TMZ (p<0.0001) and absence of corticosteroids
intake (p<0.025).
Conclusion. Combination of TMZ and radiotherapy for newly diagnosed malignant gliomas resulted in a clinically meaningful
and statistically signiﬁcant survival beneﬁt with minimal additional toxicity. Our results were similar to those reported in the
literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.125
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Introduction. Cranio-Spinal Irradiation (CSI) is technically very challenging, historically ﬁeld edge matching is needed because of
the mechanical limitations of standard linear accelerators.
